NEW YORK – The UK's National Institute for Health Care Excellence (NICE) today published a final draft guidance recommending that the National Health Service make entrectinib (Roche's Rozlytrek) available as a treatment for patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) who have not received previous ROS1 inhibitors.